Pediatric Brain Tumor Market Information, By Types (Gliomas, Mixed Neuronal-Glial Tumors, Embryonal Tumors, and others), By Diagnosis (Imaging Tests, Brain Or Spinal Cord Tumor Biopsy, and others), By Treatment, By End User- Global Forecast Till 2027
The global pediatric brain tumor market is expected to reach a valuation of USD 1,659.4 million by 2023, according to the latest research report from Market Research Future (MRFR). The global pediatric brain tumor market is mainly driven by the growing awareness about the disease and the increasing investment being made by government agencies in finding effective cures for the disease and the growing prevalence of pediatric brain cancer around the world.
Changing lifestyle factors have triggered a growth in the global prevalence of pediatric brain tumors over the last few years. This is likely to be the main driver for the global pediatric brain tumor market over the forecast period, as the growing prevalence of the disease has raised awareness among parent demographics as well as mobilizing a steady stream of funding from government healthcare agencies to study and tackle the disease. The emotional factor behind pediatric brain cancer is also likely to play a key role in the growth of the global pediatric brain tumor market over the forecast period, as promotional campaigns for pediatric cancer often get more attention from governments and the general populace alike than campaigns focusing on adult cancer.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/3690
The growing healthcare infrastructure in the U.S., Germany, the UK, France, and other leading nations around the world, and the rising funding for clinical trials is likely to be a major driver for the global pediatric brain tumor market over the forecast period. Research efforts aimed at discovering definitive cures for pediatric cancer are likely to play a key role in the growth of the global pediatric brain tumor market over the forecast period, as the causality and progression mechanism of pediatric brain cancer is not understood in its entirety.
Industrial Updates:
In April 2019, researchers at the Brain Tumor Center at Cincinnati Children’s Hospital Medical Center found a key molecular driver of glioblastoma, a major type of pediatric brain tumor. The researchers discovered that the transformation of primitive oligodendrocyte progenitors into a stem cell-like state is a key step in the growth of glioblastoma. This research, conducted on neonatal mice and laboratory models for brain cancer, ignites the hope that pediatric brain tumors can be stopped in their earliest state with further medical research targeted at finding a cure for this key conversion process.
In March 2019, doctors at the University of Michigan received a grant for nearly USD 500,000 from the National Institutes of Health, which is being used to develop effective cures for pediatric brain tumors.
Segmentation:
The global pediatric brain tumor market has been segmented on the basis of type into gliomas, mixed neuronal-glial tumors, embryonal tumors, choroid plexus papilloma/carcinoma, non-neuroepithelial tissue tumors, meningeal tumors, and others. Gliomas are further sub-segmented into astrocytomas, malignant gliomas, and others. Mixed neuronal-glial tumors are further sub-segmented into ganglioglioma, subependymal giant cell tumor, pleomorphic xanthoastrocytoma, and others. Embryonal tumors are further sub-segmented into primitive neuroectodermal tumor (PNET), atypical teratoid/rhabdoid tumor, and others. Non-neuroepithelial tissue tumors are further sub-segmented into craniopharyngioma, pineal region tumors, and others.
On the basis of diagnosis, the global pediatric brain tumor market is segmented into physical exam, imaging tests, brain or spinal cord tumor biopsy, lumbar puncture (spinal tap), blood and urine tests, and others. Imaging tests are further sub-segmented into magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), angiograms, and others. The brain or spinal cord tumor biopsy segment is further subdivided into stereotactic needle biopsy, craniotomy, and others.
On the basis of treatment, the pediatric brain tumor market is segmented into surgery, therapies, drug treatment, and others. The surgery segment is further sub-segmented into surgical biopsy, resection (removal), shunt placement/revision, and others. Therapies include radiation therapy, chemotherapy, targeted therapy, and others. Chemotherapy includes Carboplatin, Carmustine (BCNU), Cisplatin, Cyclophosphamide, Etoposide, Lomustine (CCNU), Methotrexate, Temozolomide, Thiotepa, Vincristine, and others. The drug treatment segment is further sub-segmented into corticosteroids, anti-seizure drugs (anti-epileptics), hormones, and others.
On the basis of end user, the global pediatric brain tumor market is segmented into hospitals and clinics, medical research centers, academic institutes, and others.
Regional Analysis:
North America is likely to hold the dominant share in the global pediatric brain tumor market, followed by Europe, due to the growing prevalence of pediatric brain tumors in these regions and the presence of strong, capable healthcare networks.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/pediatric-brain-tumor-market-3690
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
